摘要
原发性胆汁性胆管炎(PBC)的治疗近年来主要应用熊去氧胆酸,而增长的患者人数、应答不佳和治疗不耐受的出现对治疗方案提出了挑战,新药奥贝胆酸的获批为PBC患者带来了希望,联合使用贝特类药物也具有前景,更多的试验正在进行之中。新型药物如单克隆抗体、成纤维细胞生长因子19、钠依赖性胆汁酸转运蛋白抑制剂等虽然疗效数据有限,但为PBC治疗提供了新的方向。通过个性化随访以及分层治疗,PBC患者的管理将进入新的阶段。
In recent years,ursodeoxycholic acid is commonly used for the treatment of primary biliary cholangitis（PBC）;however,the growing number of PBC patients and the occurrence of suboptimal response and treatment intolerance pose a great challenge to treatment regimens.The approval of the new drug obeticholic acid brings hope to PBC patients,and a combination of fibrates also has a promising future.More studies are in progress.Although new drugs,such as monoclonal antibody,fibroblast growth factor 19,and sodium-dependent bile acid transporter inhibitor,have limited efficacy data,they provide new directions for the treatment of PBC.With the help of individualized follow-up and stratified therapy,the management of PBC patients will enter a new stage.
作者
施漪雯
尤红
Sill Yiwen;YOU Hong.(Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Transla- tional Medicine in Liver Cirrhosis, National Clinical Research Center for Digestive Diseases, Beijing 100050, China)
出处
《临床肝胆病杂志》
CAS
2017年第11期2101-2104,共4页
Journal of Clinical Hepatology
关键词
胆管炎
胆汁性
熊脱氧胆酸
鹅脱氧胆酸
氯贝酸
糖皮质激素类
抗体
单克隆
cholangitis, biliary
ursodeoxycholic acid
chenodeoxycholic acid
clofibric acid
glucocrticoids
antibodies, monoclonal
